Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses ...

BOSTON and LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company ...

the Company may be unable to advance our preclinical development programs into and through the clinic for safety or efficacy reasons or commercialize our product candidates or we may experience ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology ...

Activist Commentary: Elliott is a very successful and astute activist investor. The firm's team includes analysts from ...

The projected timeline to identify a preclinical measles mAb candidate in 2025 demonstrates the company's commitment to advancing its research and development efforts promptly. The press release ...

When it comes to training artificial intelligence, OpenAI and Babylon Biosciences have shown that experienced hands can help ...

Novel Kinesin program targeting ecDNA segregation and inheritance Boundless expects to nominate a development candidate for its preclinical program targeting a previously undrugged kinesin by mid ...

Slow progress, pipeline uncertainty & lack of catalysts weigh despite strong cash. Click to read why KYMR stock is a Hold.

Q1 2025 Earnings Call Transcript May 12, 2025 Xenon Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.83, ...

Based on promising preclinical data ... for the treatment of cancers with FOCAD deletion TNG961 is a development candidate targeting HBS1L in FOCAD-deleted solid tumors. FOCAD deletion occurs ...

Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) ...